Expression and clinical significance of FoxM1 isoforms in epithelial ovarian cancer
WANG Yan
LI Gang
ZUO Manzhen
Abstract：Objective To observe the expression characteristics of FoxM1 isoform in patients with epithelial ovarian cancer,and to explore its application value. Methods Fifty patients with epithelial ovarian cancer identified by pathological examination who underwent surgical therapy were regarded as malignant group,the other 50 patients with ovarian benign tumor who were identified by image and pathologic examination were served as benign group,besides,50 patients with the other gynecological diseases who had no ovary abnormality identified by image examination and clinical symptoms were regarded as control group. The ovarian pathological tissue sections were made and stained by immunohistochemistry,then the positive expression rates of FoxM1 were detected by immunofluorescence. Results There were significant differences in the positive expression rates of FoxM1 among malignant group,benign group and control group( P ﹤ 0. 01),which in malignant group were significantly higher than those in benign group and control group( P ﹤ 0. 01),moreover,which in benign group were significantly higher than those in control group( P ﹤ 0. 01). The positive expression rates of FoxM1 were closely correlated to FIGO staging,differentiation degree and lymph node metastasis of epithelial ovarian cancer( P ﹤ 0. 05 or P ﹤ 0. 01). The single factor and multiple factors analysis showed that only FIGO staging and lymph node metastasis could be regarded as independent prognostic factors in patients with epithelial ovarian cancer. Conclusion FoxM1 isoforms appear overexpression in epithelial ovarian cancer,furthermore,which are closely correlated to FIGO staging,differentiation degree,pathological typing and lymph node metastasis of epithelial ovarian cancer. The independent prognostic factors of epithelial ovarian cancer are FIGO staging,lymph node metastasis and positive expression of FoxM1.
Keywords：FoxM1 isoformepithelial ovarian cancergene expression
Publication Date：2016-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：4( 488-491 )